Difelikefalin
A peripherally restricted kappa opioid agonist that eases itch in people on hemodialysis
Difelikefalin is a selective kappa opioid receptor agonist with limited entry into the brain. Approved as Korsuva in 2021, it is injected into the dialysis line after each session for moderate-to-severe itch caused by chronic kidney disease.
Manufacturer's recommended dosing (FDA label): 0.5 µg/kg (target dry weight), After each dialysis session (typically 3 times a week), Intravenous (dialysis line) Details ↓
Recommended Dosing
Manufacturer's recommended dosing (FDA label)
From the prescribing information. Other doses studied, if any, are in the full dosing data below.
Used in human trials
No manufacturer dose exists for this use: these are amounts given in published trials, not recommendations.
What is it?
Itch caused by chronic kidney disease is common in people on hemodialysis and can be distressing enough to harm quality of life. Kappa opioid receptors help modulate itch. Difelikefalin activates them while staying largely outside the central nervous system, and it does not act on the mu receptors through which morphine-like opioids work.
In KALM-1, 49.1% of patients given difelikefalin after dialysis had a drop of at least 3 points in their worst-itch score at 12 weeks, against 27.9% on placebo. A Japanese trial found a similar benefit at 4 weeks, and pooled phase 3 data linked itch relief to better quality of life. The earlier dose-finding trial in 174 patients pointed the same way, and a meta-analysis of four trials (1,268 patients) found a 3-point improvement more likely with difelikefalin (risk ratio 1.28) but adverse events more likely as well (1.33).
Safety has been followed in larger pooled data. Across 848 patients in the placebo-controlled trials, the side effects more common on difelikefalin were diarrhoea (9.0% against 5.7%), dizziness (6.8% against 3.8%), nausea, falls and gait problems, raised potassium, headache, sleepiness and changes in mental status (3.3% against 1.4%), mostly mild or moderate; rates did not rise with longer exposure among 1,306 patients. A 2026 systematic review of 12 real-world studies (3,524 patients) found 35% to 93% reaching a 3-point itch improvement, against 51% in the pooled pivotal trials, though the studies were varied and at high risk of bias.
Outside trials the picture holds, on thinner data. A managed access programme gave it to 438 patients in Europe and Australia for a median 115 days: 10.2% of serious adverse events were judged possibly related, none of the 63 deaths was, and no new safety signal appeared in three years. In a large US dialysis organisation's records, itch scores fell a mean 2.9 points, but only 22% of 715 patients had a follow-up score, and dizziness and raised potassium rose slightly. In 20 patients with refractory itch treated for a year, scores fell by about half, while 8 stopped, 3 of them for side effects.
Two studies addressed the opioid question directly: in recreational drug users its liking scores were lower than pentazocine's, and stopping it abruptly in dialysis patients produced no withdrawal signs. It is not a controlled substance in the US. An oral form has been tested too: in a 12-week phase 2 trial in chronic kidney disease, 1.0 mg a day cut itch more than placebo, and it has been tried in other itchy conditions.
It was approved in the US as Korsuva in August 2021 and in the EU as Kapruvia in April 2022, for adults on haemodialysis with moderate-to-severe itch. It is given only as an injection into the dialysis circuit at the end of each session, so it is not used outside haemodialysis units.
Since approval the evidence has broadened in three directions. A phase 3 trial in Chinese patients on haemodialysis found the same pattern as KALM-1, with 48.7% against 33.8% gaining a 3-point itch improvement at 12 weeks. Pharmacokinetic work explains the dosing: the drug builds up as kidney function falls, but dialysis removes most of it, which is why it is given after each session. And post-marketing reports to the FDA point to the same neurological effects as the trials, changed mental status, disorientation, sleepiness and falls, most often in older patients; in the trials, patients also taking opioids had more serious adverse events whichever arm they were in.
Mechanism of Action
Difelikefalin is a kappa opioid agonist designed to stay outside the brain, so it acts on itch signalling in the body without the euphoria of mu-opioid drugs.
Kappa opioid receptor
It activates kappa opioid receptors on peripheral nerves and immune cells, which dampens itch signalling.
Kept out of the brain
It is a hydrophilic peptide that crosses the blood-brain barrier poorly, which is why abuse-potential testing found lower liking than pentazocine.
No mu-receptor action
It does not act on mu receptors, the target of morphine-like opioids, and stopping it abruptly produced no withdrawal signs.
Timed to dialysis
The label directs a dose into the venous line at the end of each haemodialysis session, so it fits the patient's existing treatment schedule rather than adding separate injections.
Published Research
The studies behind difelikefalin, read from their PubMed abstracts.
KALM-1: 378 patients on hemodialysis
Difelikefalin 0.5 µg/kg three times a week for 12 weeks gave a drop of at least 3 points in worst-itch score in 49.1% against 27.9% on placebo, and a 4-point drop in 37.1% against 17.9%; diarrhoea, dizziness and vomiting were more common.
Japan: 178 patients
After 4 weeks, the itch score fell 2.06 points against 1.09 on placebo; treatment-related adverse events occurred in 15% against 3%, mostly gastrointestinal.
Itch relief and quality of life, 914 patients
In pooled phase 3 data, quality-of-life scores improved more on difelikefalin than placebo, and most in those whose itch fell by at least 3 points.
Abuse potential in drug users
In 44 recreational drug users, high intravenous doses produced lower drug-liking scores than pentazocine, and no greater wish to take it again than placebo.
No withdrawal on stopping
In 30 dialysis patients randomized to continue or stop after three weeks, withdrawal scores did not differ; abrupt stopping produced no signs of physical withdrawal.
Oral form in notalgia paresthetica
In 125 patients with this nerve-related back itch, oral difelikefalin 2 mg twice daily lowered itch by 4.0 points against 2.4 over 8 weeks, but secondary outcomes did not support the result.
Phase 3 in Chinese patients on haemodialysis
In a randomised placebo-controlled phase 3 trial with a 12-week double-blind period, difelikefalin lowered worst-itch scores more than placebo at week 4 (difference -0.81 points), and 48.7% against 33.8% had a 3-point improvement at week 12. Adverse events were mostly mild or moderate, in line with the known profile.
Kidney function and dialysis clearance
Single 3.0 µg/kg doses gave exposure in mild kidney impairment similar to healthy people, and higher exposure with moderate or severe impairment. In 19 people on haemodialysis given 0.5 to 2.5 µg/kg after each session, exposure rose in proportion to dose, steady state came by the second dose, and dialysis removed most of the drug.
Patients also taking opioids
In the KALM-1 and KALM-2 trials, about a quarter of patients also took opioids. Difelikefalin beat placebo on itch with or without them, but serious adverse events were more common among opioid users on either treatment (44.7% against 19.0% on difelikefalin), and the authors advise careful medication management.
Post-marketing reports (FAERS)
Among 328 reports to the FDA's adverse event system from 2022 to 2025, the strongest disproportionality signals were nervous system and psychiatric: changed mental status, disorientation, an electric-shock sensation, sleepiness, falls and fractures, especially in older patients. Spontaneous reports show signals, not rates or causes.
Phase 2: three intravenous doses
In 174 haemodialysis patients with moderate-to-severe itch given intravenous difelikefalin (0.5, 1.0 or 1.5 µg/kg) or placebo after each session for 8 weeks, itch intensity fell more on the pooled doses (p = 0.002), with better itch-related quality of life and sleep; 78% on difelikefalin reported adverse events against 42% on placebo, most often diarrhoea, dizziness, nausea, sleepiness and falls.
Oral tablets in kidney disease, phase 2
In 269 people with moderate-to-severe itch and either stage 3-5 chronic kidney disease not on dialysis or haemodialysis, oral difelikefalin 1.0 mg once daily for 12 weeks lowered weekly itch scores more than placebo (p = 0.018), with complete response (a score of 0-1) in 38.6% against 14.4%; the 0.25 and 0.5 mg doses gave only numerical reductions. Common adverse events included dizziness, falls, constipation, diarrhoea and raised potassium.
Managed access: 438 patients, three years
In a managed access programme giving 438 haemodialysis patients in Europe and Australia 0.5 µg/kg after each session (median 115 days), 38.1% had adverse events; 10.2% of 246 serious events were judged possibly related, none of 63 deaths was, and no new safety signal emerged over three years.
A US dialysis organisation: 715 patients
In records from a large US dialysis organisation (715 patients, mean baseline worst-itch 8.5 of 10), the 22% with a follow-up score improved by a mean 2.9 points (8.4 to 5.4), more in those completing at least 30 doses over 12 weeks (3.6 against 2.2 points); nausea, diarrhoea and trouble walking did not increase, while dizziness (0.09% to 0.20%) and raised potassium (2.0% to 2.6%) rose slightly.
A year of treatment in refractory itch
In 20 haemodialysis patients with refractory itch treated for up to 12 months, worst-itch scores fell from 8.0 to 3.9 and itch-related sleep disturbance from 2.9 to 1.2, with no change in SF-12 quality of life; 8 (40%) stopped: 3 for adverse events, mainly diarrhoea and mild cognitive impairment, 3 who died of cardiovascular events judged unrelated, and 2 by choice.
Pooled safety, 1,306 patients
In 848 placebo-controlled patients, adverse events more frequent on difelikefalin included diarrhoea (9.0% vs 5.7%), dizziness (6.8% vs 3.8%), nausea, falls, hyperkalaemia, headache, somnolence and mental status changes; rates did not increase with long-term exposure.
Real-world evidence, 12 studies
Across 3,524 haemodialysis patients, 35% to 92.9% achieved a 3-point itch reduction against 51% in pooled KALM data; treatment-related adverse events were 6.3% to 16%; studies were heterogeneous and at high risk of bias.
Kidney injury in septic mice
In mouse models of endotoxaemia and polymicrobial sepsis, difelikefalin protected against acute kidney injury and improved survival after ischaemia-reperfusion plus endotoxin, possibly through kappa receptors on interstitial cells in the kidney.
Meta-analysis: four trials, 1,268 patients
Pooling four randomised trials in 1,268 haemodialysis patients, difelikefalin made a drop of more than 3 points in worst-itch score more likely (risk ratio 1.28, 95% CI 1.07-1.53) and lowered 5-D itch scores, but adverse events were more common too (risk ratio 1.33); the authors call for more studies.
Dosing Data
Difelikefalin (Korsuva) is given intravenously into the dialysis circuit at the end of each haemodialysis session, at a dose set by the patient's target dry body weight.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
The approved product, as its label describes it:
- Korsuva (difelikefalin injection): Injection: 65 mcg /1.3 mL (50 mcg/mL) of difelikefalin. Forms the label lists: vials.
Source: Korsuva (difelikefalin injection) label, section 3 (DailyMed version 9, effective August 26, 2025).
Mixing a vial: a worked example
Nothing to mix: the label gives Korsuva (difelikefalin injection) as vials, ready to use.
Source: Korsuva (difelikefalin injection) label, sections 2, 3 and 16 (DailyMed version 9, effective August 26, 2025).
Storage before and after mixing
Before mixing or first use: “Store vials at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).” “Do not freeze.” “Any unused drug remaining after injection must be discarded.”
After mixing or first use: “KORSUVA injection must be administered within 4 hours of syringe preparation; prepared syringes can be stored at ambient temperature 20°C to 25°C (68°F to 77°F) until dosing.”
Source: Korsuva (difelikefalin injection) label, sections 16 and 2 (DailyMed version 9, effective August 26, 2025).
How it is taken
As the approved label gives it: Intravenous (dialysis line) (After each dialysis session (typically 3 times a week); Label: haemodialysis itch).
Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: a half-life of 23 to 31 hours in hemodialysis patients, before dialysis. After about five half-lives almost none is left.
When effects appear: unknown; no source on this page gives a time to effect for Difelikefalin. Results reported in the studies are under Published Research.
Source: half-life: Korsuva prescribing information, section 12.3 (DailyMed set 0c7b81f2-0fd3-47cb-8b0f-185e07f19c87, effective August 26, 2025; read October 2, 2026).
Side effects, and when to stop or get help
From the Side Effects section: Diarrhoea, dizziness and vomiting (KALM-1); Constipation and abdominal discomfort (Japan trial); Headache and dizziness with the oral form; Falls and gait disturbance (6.6% against 5.4% in pooled data); Mental status changes (3.3% against 1.4%), more likely with other sedating medicines; Somnolence (4.2% against 2.4%) and headache (4.5% against 2.6%) in pooled data. Full list and cautions ↓
When to stop or get help: unknown; the label's warnings summary we read gives no rule for stopping Difelikefalin. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the studies above”).
Interactions
Unknown: a PubMed search for human interaction studies of Difelikefalin (reviewed 2026-10-03) found none. Unknown is not the same as safe to combine.
Every peptide's record, with its source: the interaction matrix.
Checking what you bought
Unknown: no published independent test of Difelikefalin products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Difelikefalin's expected mass, 679.8 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: FDA Approved. Sport: Not on the 2026 List.
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the studies above.
Contraindications & Cautions
Warnings from the Korsuva label (DailyMed, effective August 26, 2025).
Legal Status
Difelikefalin is approved in the US as Korsuva.
Frequently Asked Questions
?What is difelikefalin?
A kappa opioid receptor agonist with limited entry into the brain, sold as Korsuva for moderate-to-severe itch caused by chronic kidney disease in adults on hemodialysis.
?Is difelikefalin an opioid like morphine?
It acts on kappa opioid receptors rather than mu receptors. It is not a controlled substance in the US, showed low abuse potential in drug users, and stopping it caused no withdrawal in dialysis patients.
?How well does it work?
In KALM-1, 49.1% had a clinically meaningful drop in itch at 12 weeks against 27.9% on placebo.
?Is difelikefalin an opioid?
It acts on kappa opioid receptors but not on the mu receptors morphine-like drugs use; it stays largely outside the brain, testing found low abuse potential, and it is not a controlled substance in the US.
?Is it approved in Europe?
Yes, as Kapruvia, authorised by the European Medicines Agency in April 2022.
?Can it be used outside dialysis?
The injection is approved only for haemodialysis patients. An oral form has been tested in chronic kidney disease, where a 12-week phase 2 trial found 1.0 mg a day reduced itch more than placebo, and in other itchy conditions such as notalgia paresthetica, with mixed results.
?How soon does it work?
In KALM-1 the main result was measured at 12 weeks, and a Japanese trial found a benefit at 4 weeks; individual responses vary, and real-world studies report a wide range.
?What are the main side effects?
In pooled placebo-controlled data: diarrhoea, dizziness, nausea, falls, raised potassium, headache, sleepiness and changes in mental status, mostly mild or moderate.
?Does it help sleep?
Itch often disrupts sleep in dialysis patients. The 2026 review of real-world studies found that every study assessing sleep-related quality of life reported a benefit, though those studies were varied and at high risk of bias.
?Why was a drug needed for dialysis itch?
Itch from chronic kidney disease is common in people on haemodialysis and can harm sleep, mood and quality of life; difelikefalin was developed and approved specifically for that itch, given within the dialysis routine patients already follow.
References
- [fda] US FDA, Drugs@FDA (openFDA): KORSUVA (difelikefalin), NDA 214916, original approval August 23, 2021, prescription. Read October 2, 2026.
- [fda-pi] FDA. Korsuva (difelikefalin) injection US prescribing information (DailyMed set 0c7b81f2-0fd3-47cb-8b0f-185e07f19c87, version 9, effective August 26, 2025). Read October 2, 2026.
- [other] EMA medicines dataset: Kapruvia (difelikefalin), authorised April 25, 2022. Read October 5, 2026.
- [pubmed] Fishbane S, et al. "A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus." N Engl J Med, 2020;382(3):222-232. PMID: 31702883.
- [pubmed] Narita I, et al. "Difelikefalin for Hemodialysis Patients with Pruritus in Japan." NEJM Evid, 2023;2(11):EVIDoa2300094. PMID: 38320524.
- [pubmed] Ständer S, et al. "Chronic kidney disease-associated pruritus and quality of life with difelikefalin treatment: a post hoc analysis of phase 3 data using the Skindex-10 questionnaire." Clin Kidney J, 2024;17(10):sfae274. PMID: 39421431.
- [pubmed] Shram MJ, et al. "Evaluation of the abuse potential of difelikefalin, a selective kappa-opioid receptor agonist, in recreational polydrug users." Clin Transl Sci, 2022;15(2):535-547. PMID: 34708917.
- [pubmed] Spencer RH, et al. "Assessment of the physical dependence potential of difelikefalin: Randomized placebo-controlled study in patients receiving hemodialysis." Clin Transl Sci, 2023;16(9):1559-1568. PMID: 37128642.
- [pubmed] Kim BS, et al. "Phase 2 Trial of Difelikefalin in Notalgia Paresthetica." N Engl J Med, 2023;388(6):511-517. PMID: 36780675.
- [pubmed] Fishbane S, et al. "Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program." Kidney Med, 2022;4(8):100513. PMID: 36039153.
- [pubmed] Sheldon R, et al. "Real-world effectiveness and safety of difelikefalin for chronic kidney disease-associated pruritus: a systematic review." Ren Fail, 2026;48(1):2711185. PMID: 42576770.
- [clinical-trial] Zuo L, et al. "Difelikefalin in Chinese patients with chronic kidney disease-associated pruritus." Clin Kidney J, 2026;19(4):sfag031. PMID: 41948117.
- [clinical-trial] Spencer RH, et al. "Impact of renal impairment on the pharmacokinetic profile of intravenous difelikefalin, a kappa opioid receptor agonist for the treatment of pruritus." BMC Nephrol, 2024;25(1):351. PMID: 39402448.
- [pubmed] Burton JO, et al. "Influence of Concomitant Opioids on Difelikefalin Treatment Outcomes in Adults with Moderate-to-Severe Pruritus on Maintenance Hemodialysis: Exploratory Analyses." Kidney Blood Press Res, 2026;51(1):10-26. PMID: 41406043.
- [pubmed] Zhao J, et al. "Difelikefalin-associated adverse drug event signals: a real-world pharmacovigilance study from the FAERS database." Nephrol Dial Transplant, 2026. PMID: 42329786.
- [pubmed] Sawanobori Y, et al. "A kappa opioid receptor agonist, difelikefalin, improves acute kidney injury in experimental sepsis models." PLoS One, 2026;21(4):e0343693. PMID: 42013153.
- [pubmed] Fishbane S, et al. "Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients." Kidney Int Rep, 2020;5(5):600-610. PMID: 32405581.
- [pubmed] Yosipovitch G, et al. "A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus." J Am Acad Dermatol, 2023;89(2):261-268. PMID: 37059302.
- [pubmed] Xue G, et al. "Efficacy and safety of difelikefalin in the treatment of hemodialysis patients with pruritus: A meta-analysis and systematic review." Clin Nephrol, 2024;101(4):155-163. PMID: 38294219.
- [pubmed] Latus J, et al. "Real-world safety of difelikefalin for chronic kidney disease-associated pruritus: initial insights from a European managed access programme." Clin Kidney J, 2025;18(10):sfaf297. PMID: 41133182.
- [pubmed] Ficociello LH, et al. "Real-world use of difelikefalin in hemodialysis patients at a large dialysis organization in the United States: a retrospective database study." BMC Nephrol, 2025;26(1):156. PMID: 40148786.
- [pubmed] Di Giovanni M, et al. "Real-world effectiveness and tolerability of difelikefalin over 12 months for hemodialysis-associated pruritus." Int Urol Nephrol, 2026;58(8):3197-3204. PMID: 41436718.
- [pubmed] Brasme R, et al. "Recurrence of CKD-associated pruritus after discontinuation of difelikefalin." Nephrol Dial Transplant, 2025;40(9):1799-1801. PMID: 40307677.
Sources & Citations
Studies were read from their PubMed records; regulatory sources are listed below, read October 2, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.